EMAIL THIS PAGE TO A FRIEND

Nature communications

The Escherichia coli effector EspJ blocks Src kinase activity via amidation and ADP ribosylation.


PMID 25523213

Abstract

The hallmark of enteropathogenic Escherichia coli (EPEC) infection is the formation of actin-rich pedestal-like structures, which are generated following phosphorylation of the bacterial effector Tir by cellular Src and Abl family tyrosine kinases. This leads to recruitment of the Nck-WIP-N-WASP complex that triggers Arp2/3-dependent actin polymerization in the host cell. The same phosphorylation-mediated signalling network is also assembled downstream of the Vaccinia virus protein A36 and the phagocytic Fc-gamma receptor FcγRIIa. Here we report that the EPEC type-III secretion system effector EspJ inhibits autophosphorylation of Src and phosphorylation of the Src substrates Tir and FcγRIIa. Consistent with this, EspJ inhibits actin polymerization downstream of EPEC, Vaccinia virus and opsonized red blood cells. We identify EspJ as a unique adenosine diphosphate (ADP) ribosyltransferase that directly inhibits Src kinase by simultaneous amidation and ADP ribosylation of the conserved kinase-domain residue, Src E310, resulting in glutamine-ADP ribose.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

N8285
β-Nicotinamide adenine dinucleotide, pkg of 10 mg (per vial)
C21H27N7O14P2
N8410
β-Nicotinamide adenine dinucleotide, pkg of 20 mg (per vial)
C21H27N7O14P2
N8535
β-Nicotinamide adenine dinucleotide, pkg of 50 mg (per vial)
C21H27N7O14P2
N7004
β-Nicotinamide adenine dinucleotide hydrate, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
C21H27N7O14P2 · xH2O
N6522
β-Nicotinamide adenine dinucleotide hydrate, ≥98%, BioUltra, from yeast
C21H27N7O14P2 · xH2O
N1636
β-Nicotinamide adenine dinucleotide hydrate, purified by column chromatography, ≥99%
C21H27N7O14P2 · xH2O
N3014
β-Nicotinamide adenine dinucleotide hydrate, cell culture tested, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
C21H27N7O14P2 · xH2O
N7381
β-Nicotinamide adenine dinucleotide hydrate, Grade AA-1, ≥95% (HPLC)
C21H27N7O14P2 · xH2O
N1511
β-Nicotinamide adenine dinucleotide hydrate, ≥99%
C21H27N7O14P2 · xH2O
43410
β-Nicotinamide adenine dinucleotide hydrate, ≥95% (HPLC)
C21H27N7O14P2 · xH2O
N7132
β-Nicotinamide adenine dinucleotide lithium salt from Saccharomyces cerevisiae, ≥95%
C21H26LiN7O14P2
B0375
Barbital
C8H12N2O3
31995
Barbital, BioXtra, ≥99.0% (T)
C8H12N2O3
B0300000
Barbital, European Pharmacopoeia (EP) Reference Standard
C8H12N2O3
633178
Deuterium oxide, 99.994 atom % D, contains 1 mM terephthalic acid disodium salt, 0.01 % (w/v) DSS-d6
D2O
613398
Deuterium oxide, extra, 99.994 atom % D
D2O
191701
Deuterium oxide, "100%", 99.990 atom % D
D2O
364312
Deuterium oxide, standard, 99.98 atom %±0.01 atom % D
D2O
151890
Deuterium oxide, "100%", ≥99.96 atom % D
D2O
269786
Deuterium oxide, "100%", 99.96 atom % D
D2O
151882
Deuterium oxide, 99.9 atom % D
D2O
530867
Deuterium oxide, 99.9 atom % D
D2O
613444
Deuterium oxide, 99.9 atom % D, glass distilled
D2O
450510
Deuterium oxide, 99.9 atom % D, contains 0.05 wt. % 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt
D2O
293040
Deuterium oxide, 99.9 atom % D, contains 0.75 wt. % 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt
D2O
343773
Deuterium oxide, 99.9 atom % D, contains 1 % (w/w) 3-(trimethylsilyl)-1-propanesulfonic acid, sodium salt (DSS)
D2O
347167
Deuterium oxide, 99.9 atom % D, ~150 dpm/mL tritium
D2O
617385
Deuterium oxide, 99.8 atom % D
D2O
435767
Deuterium oxide, 99 atom % D
D2O
613436
Deuterium oxide, 60 atom % D
D2O